DexTech Medical AB, Interim report July 1 - September 30, 2020
First Quarter Summary (July - September 2020) • Net sales amounted to MSEK 0.0 (0.0) • Operating profit/loss amounted to MSEK -1.5 (-2.0) • Earnings per share * SEK -0.10 (-0.13) • Cash and cash equivalents at the end of the period amounted to MSEK 5.5 (8.2) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 14,920,478. For the comparison period, the average number of shares was 14,887,678. Amounts in brackets refer to the corresponding period last year. CEO's comment In June 2020, DexTech's Phase IIb study of